The US Food and Drug Administration (USFDA) is conducting a surprise inspection of Dr Reddy's Laboratories' Visakhapatnam plant. The inspection, which started on Tuesday, is expected to continue till the end of the week. The surprise check by the regulator is at the chemical technical operation (CTO) unit VI, which manufactures both active pharmaceutical ingredients (APIs) and bulk drugs. When contacted, a DRL spokesperson confirmed the developments: "We are still awaiting the report from USFDA and cannot comment on any issues," the spokesperson said, without explaining the reasons for the sudden inspection on the unit. "The inspection may continue till the end of the week and we are confident that we have maintained high quality standards including strict compliance," sources in the know said. The unit, set up in 1990, has a reaction volume capacity of over 570 KL, and is USFDA-inspected and ISO-9001 certified.